<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2010222771
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cefuroxime-Venus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFUROXIME SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VENUS REMEDIES LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefuroxime-Venus is an antibiotic used in adults and children. It works by killing bacteria that cause infections. It belongs to a group of medicines called <em>cephalosporins.</em></p><p><strong>Cefuroxime-Venus is used to treat infections of:</strong></p><ul><li>the lungs or chest</li><li>the urinary tract</li><li>the skin and soft tissue</li><li>the abdomen</li></ul><p>Cefuroxime-Venus is also used:</p><ul><li>to prevent infections during surgery.</li></ul><p>Your doctor may test the type of bacteria causing your infection and monitor whether the bacteria are sensitive to Cefuroxime-Venus during your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You must not be given Cefuroxime-Venus</p><ul><li>if you are allergic to any cephalosporin antibiotics or any of the other ingredients of Cefuroxime-Venus.</li><li>if you have ever had a severe allergic (<em>hypersensitive</em>) reaction to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems).</li></ul><p>Tell your doctor before you start on Cefuroxime-Venus if you think that this applies to you. You must not be given Cefuroxime-Venus</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before you are given Cefuroxime-Venus.</p><p>You must look out for certain symptoms such as allergic reactions, skin rashes, gastrointestinal disorders such as diarrhoea or fungal infections while you are being given Cefuroxime. This will reduce the risk of possible problems. If you have had any allergic reaction to other antibiotics such as penicillin, you may also be allergic to Cefuroxime.</p><p>If you need a blood or urine test</p><p>Cefuroxime-Venus can affect the results of urine or blood tests for sugar and a blood test known as the</p><p><em>Coombs test</em>. If you are having tests:</p><p>➔ <strong>Tell the person taking the sample </strong>that you have been given Cefuroxime-Venus.</p><p>Other medicines and Cefuroxime-Venus</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines you can obtain without a prescription.</p><p>Some medicines may affect how Cefuroxime works, or make it more likely that you&rsquo;ll have side effects. These include:</p><ul><li>aminoglycoside-type antibiotics</li><li><strong>water tablets </strong>(diuretics), such as furosemide</li><li>probenecid</li></ul><p><strong>oral anticoagulants</strong></p><p>➔ <strong>Tell your doctor </strong>if this applies to you. You may need extra check-ups to monitor your renal function while you are taking&nbsp; Cefuroxime-Venus</p><p>&nbsp;</p><p>Contraceptive pills</p><p>Cefuroxime-Venus may reduce the effectiveness of the contraceptive pill. If you are taking the contraceptive pill while you are being treated with Cefuroxime-Venus you also need to use <strong>a barrier method of contraception </strong>(such as a condom). Ask your doctor for advice.</p><p>&nbsp;</p><p>Pregnancy, breast-feeding and fertility</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this medicine.</p><p>Your doctor will consider the benefit of treating you with Cefuroxime-Venus against the risk to your baby.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Cefuroxime-Venus should not affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>Cefuroxime-Venus</strong><strong> contains </strong>39mg sodium in each vial. This is equivalent to 1.95 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>You need to take this into consideration if you are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuroxime-Venus </strong>is <strong>usually given by a doctor or nurse. </strong>It can be given as a drip (intravenous infusion) or as an injection directly into a vein or into a muscle.</p><p>&nbsp;</p><p>The recommended dose</p><p>The correct dose of Cefuroxime-Venus will be decided by your doctor and depends on:</p><p>the severity and type of infection, whether you are on any other antibiotics, your weight and age and how well your kidneys are working.</p><p>&nbsp;</p><p>Use in adults and adolescents:</p><p>750mg to 1.5g of Cefuroxime two, three or four times daily. Maximum dose: 6g per day.</p><p>&nbsp;</p><p>Use in babies (over 3 weeks) and children:</p><p><strong>For every 1kg the baby or child weighs</strong>, they&rsquo;ll be given 30 to 100mg of Cefuroxime per day divided in three or four doses.</p><p>&nbsp;</p><p>Use in newborn babies (0 -3 weeks):</p><p><strong>For every 1kg the baby weighs, </strong>they&rsquo;ll be given 30 to 100mg Cefuroxime per day divided in two or three doses.</p><p>&nbsp;</p><p>Patients with kidney problems</p><p>If you have a kidney problem your doctor may change your dose.</p><p>➔ <strong>Talk to your doctor </strong>if this applies to you.</p><p>&nbsp;</p><p>If you are given more Cefuroxime-Venus than you should receive</p><p>It is unlikely that you will be given too much, but if you think that you have been given too much Cefuroxime-Venus, tell your doctor, pharmacist or nurse immediately. Signs might include fits (convulsions).</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. All medicines can cause allergic reactions, although serious allergic reaction are very rare.</p><p>&nbsp;</p><p>Contact a doctor or nurse immediately if you get any of these symptoms:</p><ul><li>High temperature (fever), a sore throat or other signs of an infection. <strong>Common (may affect up to 1 in 10 people)</strong></li><li>Abnormal reduction in white blood cells (leucopenia) &ndash; shown by blood tests. <strong>Uncommon (may affect up to 1 in 100 people)</strong></li><li>Get potentially serious allergic reactions. Symptoms of these reactions include:&nbsp;<strong>severe allergic reaction</strong>. Signs include <strong>raised and itchy rash</strong>, <strong>swelling</strong>, sometimes of the face or mouth causing <strong>difficulty in breathing</strong>.</li><li><strong>skin rash, </strong>which may <strong>blister</strong>, and looks like <strong>small targets </strong>(central dark spot surrounded by a paler area, with a dark ring around the edge)</li><li><strong>a widespread rash </strong>with <strong>blisters </strong>and <strong>peeling skin. </strong>(These may be signs of <em>Stevens-Johnson syndrome </em>or <em>toxic epidermal necrolysis</em>). <strong>Not known (cannot be estimated from available data)</strong></li><li><strong>fungal infections </strong>on rare occasions, medicines like Cefuroxime can cause an overgrowth of yeast (<em>Candida</em>) in the body which can lead to fungal infections (such as thrush). This side effect is more likely if you take Cefuroxime for a long time. <strong>Not known (cannot be estimated from available data)</strong></li><li><strong>severe diarrhoea (<em>Pseudomembranous colitis</em>). </strong>Medicines like Cefuroxime can cause inflammation of the colon (large intestine), causing severe diarrhoea, usually with blood and mucus, stomach pain, fever. <strong>Not known (cannot be estimated from available data)</strong></li><li>Decrease in the number of platelets in the blood resulting in bruising easily or episodes of excessive bleeding (Thrombocytopenia and haemolytic anaemia). <strong>Not known (cannot be estimated from available data)</strong></li><li>Changes in kidney function shown by blood or urine tests. <strong>Not known (cannot be estimated from available data)</strong></li></ul><p><strong>&nbsp;</strong></p><p>Other side effects have also been reported:</p><p>Common (may affect up to 1 in 10 people)</p><ul><li>Temporary pain at the injection site</li><li>Temporary changes in your blood such as reduced red blood cells and reduced hemoglobin levels or changes in liver function, which will be shown by blood tests</li></ul><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people)</p><ul><li>Rash</li><li>Itchy red wheals (urticaria)</li><li>Diarrhoea and nausea (feeling sick)</li><li>Temporary yellowing of the skin and whites of the eyes which usually return to normal after treatment (due to an increase in a substance made in the liver called bilirubin)</li><li>Positive Coombes test (blood test)</li></ul><p>&nbsp;</p><p>Not known (cannot be estimated from available data)</p><ul><li>High temperature and chills (fever)</li></ul><p>Side effects that may show up in blood tests:</p><ul><li>decrease in number of blood platelets (cells that help blood to clot - <em>thrombocytopenia</em>)</li><li>increase in levels of urea nitrogen and serum creatinine in the blood.</li></ul><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your Registered doctor, Pharmacist or nurse.</p><p><strong>To report any side effect(s): </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefuroxime-Venus </strong>is for use in hospital only and the expiry date and storage instructions stated on the vial label and carton are for the doctor, nurse or pharmacist&rsquo;s information. The doctor, pharmacist or nurse will make up your medicine.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C. Protect from light.</p><p>After reconstitution the product may be stored at 2&deg;C-8&deg;C (in a refrigerator) for up to 24 hours.</p><p>Keep the vial in the outer carton in order to protect from light. For single use only. Discard any unused contents.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Vial Contains</p><p>Cefuroxime Sodium Ph.Eur</p><p>Eqv. to Cefuroxime .... ... ..... 750mg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cefuroxime-Venus contains 750 mg of Cefuroxime Sodium, in 10 ml clear moulded glass vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>VENUS Remedies Limited. </strong></p><p>Hill Top Industrial Estate, Jharmajri,EPIP, Phase-I</p><p>(Extn.), Bhatoli Kalan, Baddi, Distt. Solan,</p><p>Himachal Pradesh-173205, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                XX
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيفوروكسيم فينوس مضاد حيوي يستخدم للبالغين والأطفال. وهو يعمل عن طريق قتل البكتيريا المسببة للالتهابات. إنه ينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL"><strong>يستخدم سيفوروكسيم فينوس لعلاج التهابات</strong><strong>:</strong></p><p dir="RTL">&nbsp;-&nbsp; الرئتين أو الصدر</p><p dir="RTL">- المسالك البولية</p><p dir="RTL">- الجلد والأنسجة الرخوة</p><p dir="RTL">- البطن</p><p dir="RTL">يستخدم سيفوروكسيم فينوس أيضًا:</p><p dir="RTL">- لمنع الالتهابات أثناء الجراحة.</p><p dir="RTL">قد يختبر طبيبك نوع البكتيريا المسببة للعدوى ويراقب ما إذا كانت البكتيريا حساسة لسيفوروكسيم فينوس أثناء العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا تحصل على سيفوروكسيم فينوس</strong></p><p dir="RTL">- إذا كنت تعاني من حساسية تجاه أي من المضادات الحيوية للسيفالوسبورين أو أي من المكونات الأخرى لسيفوروكسيم فينوس.</p><p dir="RTL">&nbsp;- إذا كان لديك في أي وقت مضى رد فعل تحسسي شديد (شديد الحساسية) لأي نوع آخر من المضادات الحيوية بيتالاكتام (بنسلين ، مونوباكتام ، كاربابينيم).</p><p dir="RTL">أخبر طبيبك قبل أن تبدأ باستخدام سيفوروكسيم فينوس إذا كنت تعتقد أن هذا ينطبق عليك. يجب ألا تحصل على سيفوروكسيم فينوس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل أن تتناول سيفوروكسيم فينوس.</p><p dir="RTL">يجب أن تبحث عن أعراض معينة مثل الحساسية والطفح الجلدي واضطرابات الجهاز الهضمي مثل الإسهال أو الالتهابات الفطرية أثناء تناول سيفوروكسيم. هذا سوف يقلل من مخاطر المشاكل المحتملة. إذا كان لديك أي رد فعل تحسسي تجاه المضادات الحيوية الأخرى مثل البنسلين ، فقد يكون لديك أيضًا حساسية من سيفوروكسيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت بحاجة إلى فحص دم أو بول</strong></p><p dir="RTL">يمكن أن يؤثر سيفوروكسيم فينوس على نتائج اختبارات البول أو الدم لقياس السكر واختبار الدم المعروف باسم</p><p dir="RTL">اختبار كومبس. إذا كنت ستخضع لاختبارات:</p><p dir="RTL"><strong>أخبر</strong><strong> </strong><strong>الشخص</strong><strong> </strong><strong>الذي</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>العينة</strong> أنك قد تناولت سيفوروكسيم فينوس.</p><p dir="RTL"><strong>أدوية أخرى وسيفوروكسيم فينوس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. وهذا يشمل الأدوية التي يمكنك الحصول عليها بدون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على كيفية عمل سيفوروكسيم ، أو تزيد من احتمالية حدوث آثار جانبية. وتشمل هذه:</p><p dir="RTL"><strong>- </strong><strong>مضادات حيوية من نوع أمينوغليكوزيد</strong></p><p dir="RTL"><strong>- </strong><strong>أقراص الماء </strong><strong>(</strong><strong>مدرات البول</strong><strong>) </strong><strong>مثل فوروسيميد</strong></p><p dir="RTL"><strong>- </strong><strong>بروبينسيد</strong></p><p dir="RTL"><strong>- </strong><strong>مضادات التخثر الفموية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا كان هذا ينطبق عليك. قد تحتاج إلى فحوصات إضافية لمراقبة وظائف الكلى أثناء تناول سيفوروكسيم فينوس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حبوب منع الحمل</strong></p><p dir="RTL">قد يقلل سيفوروكسيم فينوس من فعالية حبوب منع الحمل. إذا كنت تتناول حبوب منع الحمل أثناء علاجك بسيفوروكسيم فينوس ، فأنت بحاجة أيضًا إلى استخدام <strong>وسيلة مانعة للحمل</strong> (مثل الواقي الذكري).<strong> </strong>إسأل طبيبك للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">إذا كنت حاملاً أو مرضعة ، تعتقدين أنك حامل أو تخططين لإنجاب طفل ، استشيري طبيبك أو الصيدلي قبل إعطائك هذا الدواء.</p><p dir="RTL">سينظر طبيبك في فائدة علاجك بسيفوروكسيم فينوس ضد المخاطر التي يتعرض لها طفلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>السياقة واستعمال الماكنات</strong></p><p dir="RTL">يجب ألا يؤثر سيفوروكسيم فينوس على قدرتك على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيفوروكسيم فينوس</strong> على 39 ملغ صوديوم في كل قنينة. هذا يعادل 1.95٪ من الحد الأقصى الموصى به من المدخول الغذائي اليومي من صوديوم للشخص البالغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تأخذ ذلك في الاعتبار إذا كنت تتبع نظامًا غذائيًا مضبوطًا بالصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عادة ما يتم إعطاء سيفوروكسيم فينوس بواسطة طبيب أو ممرضة</strong>. يمكن إعطاؤه على شكل تنقيط (تسريب في الوريد) أو كحقن مباشرة في الوريد أو في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">سيحدد طبيبك الجرعة الصحيحة من سيفوروكسيم فينوس وتعتمد على:</p><p dir="RTL">شدة العدوى ونوعها ، سواء كنت تتناول أي مضادات حيوية أخرى ، ووزنك وعمرك ومدى كفاءة عمل كليتيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدم في البالغين والمراهقين</strong><strong>:</strong></p><p dir="RTL">750 مجم إلى 1.5 جرام سيفوروكسيم مرتين أو ثلاث أو أربع مرات يوميًا. الجرعة القصوى: 6 جرام في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدم في الأطفال </strong><strong>(</strong><strong>أكثر من </strong><strong>3</strong><strong> </strong><strong>أسابيع</strong><strong>) </strong><strong>والأطفال</strong><strong>:</strong></p><p dir="RTL"><strong>مقابل كل كيلوغرام من وزن الطفل أو الرضيع</strong> ، سيتم إعطاؤهم 30 إلى 100 مجم من سيفوروكسيم يوميًا مقسمة على ثلاث أو أربع جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال حديثي الولادة </strong><strong>(</strong><strong>0</strong><strong>-</strong><strong>3</strong><strong> </strong><strong>أسابيع</strong><strong>):</strong></p><p dir="RTL"><strong>مقابل كل كيلوغرام من وزن الطفل</strong> ، سيتم إعطاؤهم 30 إلى 100 مجم سيفوروكسيم يوميًا مقسمة على جرعتين أو ثلاث جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">إذا كنت تعاني من مشكلة في الكلى ، فقد يقوم طبيبك بتغيير جرعتك.</p><p dir="RTL"><strong>تحدث</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>طبيبك</strong> إذا كان هذا ينطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك سيفوروكسيم فينوس أكثر مما يجب أن تتناوله</strong></p><p dir="RTL">من غير المحتمل أن يتم إعطاؤك أكثر من اللازم ، ولكن إذا كنت تعتقد أنك قد تم إعطاؤك الكثير من سيفوروكسيم فينوس ، أخبر طبيبك أو الصيدلي أو الممرضة على الفور. قد تشمل العلامات نوبات (تشنجات).</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع. يمكن لجميع الأدوية أن تسبب ردود فعل تحسسية ، على الرغم من أن رد الفعل التحسسي الخطير نادر جدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بطبيب أو ممرضة على الفور إذا ظهرت عليك أي من هذه الأعراض</strong><strong>:</strong></p><p dir="RTL"><strong>- </strong>إرتفاع في درجة الحرارة (حمى) ، إلتهاب في الحلق أو علامات أخرى للالتهاب. <strong>شائعة</strong> (<strong>قد تظهر لدى حتى </strong><strong>1</strong><strong> </strong><strong>من كل </strong><strong>10</strong><strong> </strong><strong>أشخاص</strong>)</p><p dir="RTL"><strong>- </strong>انخفاض غير طبيعي في خلايا الدم البيضاء (قلة الكريات البيض) - تظهر بفحوصات الدم. <strong>غير شائعة</strong> (<strong>قد تظهر لدى حتى </strong><strong>1</strong><strong> </strong><strong>من كل </strong><strong>100</strong><strong> </strong><strong>شخص</strong>)</p><p dir="RTL"><strong>- </strong>لديك ردود فعل تحسسية خطيرة. تشمل أعراض هذه التفاعلات:</p><p dir="RTL"><strong>رد فعل تحسسي </strong>شديد<strong>.</strong> تشمل العلامات <strong>طفح جلدي مرتفع ومثير</strong> للحكة وتورم وأحيانًا في الوجه أو الفم مما يسبب <strong>صعوبة في التنفس</strong>.</p><p dir="RTL"><strong>- </strong><strong>طفح جلدي</strong> ، <strong>قد ينفخ</strong> ، ويبدو وكأنه <strong>أهداف صغيرة</strong> (بقعة داكنة مركزية محاطة بمنطقة شاحبة ، مع حلقة داكنة حول الحافة)</p><p dir="RTL"><strong>- </strong><strong>طفح جلدي واسع الانتشار</strong> مع <strong>ظهوربثور وتقشر في الجلد</strong>. (قد تكون هذه علامات لمتلازمة ستيفنز جونسون أو انحلال البشرة النخري السمي). <strong>غير معروف</strong> (<strong>لا يمكن تقديره من البيانات المتاحة</strong>)</p><p dir="RTL"><strong>- </strong><strong>التهابات فطرية</strong> في حالات نادرة ، أدوية مثل سيفوروكسيم يمكن أن تسبب فرط نمو الخميرة (المبيضات) في الجسم مما قد يؤدي إلى التهابات فطرية (مثل القلاع). تزداد احتمالية حدوث هذا التأثير الجانبي إذا تناولت سيفوروكسيم لفترة طويلة. <strong>غير</strong> <strong>معروف</strong> (<strong>لا يمكن تقديره من البيانات المتاحة</strong>)</p><p dir="RTL"><strong>- </strong><strong>إسهال شديد</strong> <strong>(</strong><strong>التهاب القولون الغشائي الكاذب</strong><strong>)</strong>. يمكن أن تسبب الأدوية مثل سيفوروكسيم التهاب القولون (الأمعاء الغليظة) ، مما يسبب إسهالًا شديدًا ، عادةً مصحوبًا بالدم والمخاط ، وآلام في المعدة ، وحمى. <strong>غير معروف</strong> (<strong>لا يمكن تقديره من البيانات المتاحة</strong>)</p><p dir="RTL"><strong>- </strong>انخفاض في عدد الصفائح الدموية في الدم مما يؤدي إلى حدوث كدمات بسهولة أو نوبات نزيف مفرط (قلة الصفيحات وفقر الدم الانحلالي). <strong>غير معروف</strong> (<strong>لا يمكن تقديره من البيانات المتاحة</strong>)</p><p dir="RTL">- تغيرات في وظائف الكلى تظهر بفحوصات الدم أو البول. <strong>غير معروف</strong> (<strong>لا يمكن تقديره من البيانات المتاحة</strong>)</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ أيضًا عن آثار جانبية أخرى:</p><p dir="RTL"><strong>شائعة </strong><strong>(</strong><strong>قد تظهر لدى حتى </strong><strong>1</strong><strong> </strong><strong>من كل </strong><strong>10</strong><strong> </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">- ألم مؤقت في مكان الحقن</p><p dir="RTL">- تغيرات مؤقتة في الدم مثل انخفاض خلايا الدم الحمراء وانخفاض مستويات الهيموجلوبين أو تغيرات في وظائف الكبد ، والتي ستظهر بفحوصات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong><strong>(</strong><strong>قد تظهر لدى حتى </strong><strong>1</strong><strong> </strong><strong>من كل </strong><strong>100</strong><strong> </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">- طفح جلدي</p><p dir="RTL">- شروخ حمراء مثيرة للحكة (شرى)</p><p dir="RTL">- إسهال وغثيان (الشعور بالمرض)</p><p dir="RTL">- اصفرار مؤقت للجلد وبياض العينين والذي عادة ما يعود إلى طبيعته بعد العلاج (بسبب زيادة مادة مصنوعة في الكبد تسمى البيليروبين)</p><p dir="RTL">- اختبار كومبس إيجابي (فحص دم)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروف </strong><strong>(</strong><strong>لا يمكن تقديره من البيانات المتاحة</strong><strong>)</strong></p><p dir="RTL">- ارتفاع في درجة الحرارة وقشعريرة (حمى).</p><p dir="RTL">الأعراض الجانبية التي قد تظهر في فحوصات الدم:</p><p dir="RTL">- انخفاض في عدد الصفائح الدموية (الخلايا التي تساعد على تخثر الدم - قلة الصفيحات الدموية).</p><p dir="RTL">إرتفاع نسب اليوريا آزوت وكرياتينين المصل في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا كنت تعاني من أي آثار جانبية ، فتحدث إلى طبيبك المسجل أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المملكة العربية السعودية:</p><p dir="RTL">المركز الوطني للتيقظ والسلامة الدوائية (NPC)</p><p dir="RTL">- فاكس: +966-11-205-7662</p><p dir="RTL">- اتصل بـ NPC على&nbsp; +966-11-2038222, هواتف فرعية : &nbsp;2317-2356-2353-2354-2334-2340.&nbsp;</p><p dir="RTL">- هاتف مجاني: 8002490000</p><p dir="RTL">- بريد إلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">- موقع: www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيفوروكسيم فينوس هو للاستخدام في المستشفى فقط وتاريخ انتهاء الصلاحية وتعليمات التخزين المذكورة على ملصق القارورة والكرتون هي لمعلومات الطبيب أو الممرضة أو الصيدلي. سيقوم الطبيب أو الصيدلي أو الممرضة بتحضير دوائك.</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">لا يجوز التخزين فوق 30 درجة مئوية. احم من الضوء.</p><p dir="RTL">بعد إعادة التركيب ، يمكن تخزين المنتج عند 2 درجة مئوية إلى 8 درجات مئوية (في الثلاجة) لمدة تصل إلى 24 ساعة.</p><p dir="RTL">احتفظ بالقارورة في الكرتون الخارجي لحمايتها من الضوء. للاستخدام الفردي فقط. تجاهل أي محتويات غير مستخدمة.</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كل قنينة تحتوي على</p><p dir="RTL">سيفوروكسيم صوديوم Ph.Eur</p><p dir="RTL">مكافئ. لسيفوروكسيم .... ..... 750 ملغ</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي سيفوروكسيم فينوس على 750 مجم من سيفوروكسيم الصوديوم ، في قنينة زجاجية شفافة مصبوب سعة 10 مل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة فينوس ريميديس&nbsp;المحدودة</strong></p><p dir="RTL">منطقة هيل توب الصناعية الشرقية، جرماجري EPIP,</p><p dir="RTL">فيس - 1(إيكستن.)، بهاتولي كالان بادي بمديرية سولان&nbsp; هيماجل براديش 173205، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            XX
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefuroxime-Venus (Cefuroxime 750 mg Powder for Solution for Injection and Infusion)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each Vial Contains
Cefuroxime Sodium Ph. Eur
Eqv. to Cefuroxime .... ... ..... 750 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Injection or Infusion
white odorless crystalline powder, free from extraneous particles, contained in 10 ml colorless glass vials with rubber plug and flip off seal.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefuroxime sodium for injection is indicated for the treatment of infections listed below in adults and children, including neonates (from birth) (see sections 4.4 and 5.1).</p><p>&bull; Community acquired pneumonia</p><p>&bull; Acute exacerbations of chronic bronchitis</p><p>&bull; Complicated urinary tract infections, including pyelonephritis</p><p>&bull; Soft-tissue infections: cellulitis, erysipelas and wound infections</p><p>&bull; Intra-abdominal infections (see section 4.4)</p><p>&bull; Prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynecological surgery (including caesarean section)</p><p>In the treatment and prevention of infections in which it is very likely that anaerobic organisms will be encountered, cefuroxime should be administered with additional appropriate antibacterial agents.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Table 1. Adults and children &ge; 40 kg</p><table border="0" cellspacing="0" cellpadding="0" style="width:665px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia and acute exacerbations of chronic bronchitis</p></td><td rowspan="3" style="vertical-align:top"><p>750 mg every 8 hours</p><p>(intravenously or intramuscularly)</p></td></tr><tr><td style="vertical-align:top"><p>Soft-tissue infections: cellulitis, erysipelas and wound infections.</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections, including pyelonephritis</p></td><td style="vertical-align:top"><p>1.5 g every 8 hours</p><p>(intravenously or intramuscularly)</p></td></tr><tr><td style="vertical-align:top"><p>Severe infections</p></td><td style="vertical-align:top"><p>750 mg every 6 hours (intravenously)</p><p>1.5 g every 8 hours (intravenously)</p></td></tr><tr><td style="vertical-align:top"><p>Surgical prophylaxis for gastrointestinal, gynaecological surgery (including caesarean section) and orthopaedic operations</p></td><td style="vertical-align:top"><p>1.5 g with the induction of anaesthesia. This may be supplemented with two 750 mg doses (intramuscularly) after 8 hours and 16 hours.</p></td></tr><tr><td style="vertical-align:top"><p>Surgical prophylaxis for cardiovascular and oesophageal operations</p></td><td style="vertical-align:top"><p>1.5 g with induction of anaesthesia followed by 750 mg (intramuscularly) every 8 hours for a further 24 hours.</p></td></tr></tbody></table><p>Table 2. Children &lt; 40 kg</p><table border="0" cellspacing="0" cellpadding="0" style="width:665px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Infants and toddlers &gt; 3 weeks and children &lt; 40 kg</strong></p></td><td style="vertical-align:top"><p><strong>Infants (birth to 3 weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td><td rowspan="4" style="vertical-align:top"><p>30 to 100 mg/kg/day (intravenously) given as 3 or 4 divided doses; a dose of 60 mg/kg/day is appropriate for most infections</p></td><td rowspan="4" style="vertical-align:top"><p>30 to 100 mg/kg/day (intravenously) given as 2 or 3 divided doses (see section 5.2)</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections, including pyelonephritis</p></td></tr><tr><td style="vertical-align:top"><p>Soft-tissue infections: cellulitis, erysipelas and wound infections</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr></tbody></table><p><u>Renal impairment</u></p><p>Cefuroxime is primarily excreted by the kidneys. Therefore, as with all such antibiotics, in patients with markedly impaired renal function it is recommended that the dosage of Cefuroxime should be reduced to compensate for its slower excretion.</p><p>Table 3. Recommended doses for Cefuroxime in renal impairment</p><table border="0" cellspacing="0" cellpadding="0" style="width:665px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><strong>T1/2 (hrs)</strong></p></td><td style="vertical-align:top"><p><strong>Dose mg</strong></p></td></tr><tr><td style="vertical-align:top"><p>&gt; 20 mL/min/1.73 m2</p></td><td style="vertical-align:top"><p>1.7&ndash;2.6</p></td><td style="vertical-align:top"><p>It is not necessary to reduce the standard dose (750 mg to 1.5 g three times daily).</p></td></tr><tr><td style="vertical-align:top"><p>10-20 mL/min/1.73 m2</p></td><td style="vertical-align:top"><p>4.3&ndash;6.5</p></td><td style="vertical-align:top"><p>750 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 mL/min/1.73 m2</p></td><td style="vertical-align:top"><p>14.8&ndash;22.3</p></td><td style="vertical-align:top"><p>750 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Patients on ha</p><p>emodialysis</p></td><td style="vertical-align:top"><p>3.75</p></td><td style="vertical-align:top"><p>A further 750 mg dose should be given intravenously or intramuscularly at the end of each dialysis; in addition to parenteral use, cefuroxime sodium can be incorporated into the peritoneal dialysis fluid (usually 250 mg for every 2 litres of dialysis fluid).</p></td></tr><tr><td style="vertical-align:top"><p>Patients in renal failure on continuous arteriovenous haemodialysis (CAVH) or high-flux haemofiltration (HF) in intensive therapy units</p></td><td style="vertical-align:top"><p>7.9&ndash;12.6 (CAVH)</p><p>1.6 (HF)</p></td><td style="vertical-align:top"><p>750 mg twice daily; for low-flux haemofiltration follow the dosage recommended under impaired renal function.</p></td></tr></tbody></table><p><u>Hepatic impairment</u></p><p>Cefuroxime is primarily eliminated by the kidney. In patients with hepatic dysfunction this is not expected to effect the pharmacokinetics of cefuroxime</p><p><u>Method of administration</u></p><p>Cefuroxime should be administered by intravenous injection over a period of 3 to 5 minutes directly into a vein or via a drip tube or infusion over 30 to 60 minutes, or by deep intramuscular injection. Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than 750 mg should be injected at one site. For doses greater than 1.5 g intravenous administration should be used. For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p><p>750 mg powder for solution for infusion.</p><p>For instructions on preparation of the medicinal product before administration, see section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to cefuroxime or to any of the excipients listed in section 6.1.
Patients with known hypersensitivity to cephalosporin antibiotics.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be initiated.</p><p>Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>Cephalosporin antibiotics may, in general, be given safely to patients who are hypersensitive to penicillins, although cross-reactions have been reported. Special care is indicated in patients who have experienced an anaphylactic reaction to penicillin.</p><p><u>Concurrent treatment with potent diuretics or aminoglycosides</u></p><p>Cephalosporin antibiotics at high dosage should be given with caution to patients receiving concurrent treatment with potent diuretics such as furosemide or aminoglycosides. Renal impairment has been reported during use of these combinations. Renal function should be monitored in the elderly and those with known pre-existing renal impairment (see section 4.2).</p><p><u>Overgrowth of non-susceptible microorganisms</u></p><p>Use of cefuroxime may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium difficile), which may require interruption of treatment (see section 4.8).</p><p>Antibacterial agent&ndash;associated pseudomembranous colitis has been reported with use of cefuroxime and may range in severity from mild to life threatening. This diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime (see section 4.8). Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p><u>Intra-abdominal infections</u></p><p>Due to its spectrum of activity, cefuroxime is not suitable for the treatment of infections caused by Gram-negative non-fermenting bacteria (see section 5.1).</p><p><u>Interference with diagnostic tests</u></p><p>The development of a positive Coombs Test associated with the use of cefuroxime may interfere with cross matching of blood (see section 4.8).</p><p>Slight interference with copper reduction methods (Benedict&#39;s, Fehling&#39;s, Clinitest) may be observed. However, this should not lead to false-positive results, as may be experienced with some other cephalosporins.</p><p>As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime sodium.</p><p><u>Intracameral use and eye disorders</u></p><p>Cefuroxime is not formulated for intracameral use. Individual cases and clusters of serious ocular adverse reactions have been reported following unapproved intracameral use of cefuroxime sodium compounded from vials approved for intravenous/intramuscular administration. These reactions included macular oedema, retinal oedema, retinal detachment, retinal toxicity, visual impairment, visual acuity reduced, vision blurred, corneal opacity and corneal oedema.</p><p>&nbsp;</p><p><u>Important information about excipients</u></p><p>Cefuroxime powder for solution for injection and infusion contains 40.6 mg sodium per 750mg vial, equivalent to 2% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This should be considered for patients who are on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefuroxime may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. Concomitant use of probenicid is not recommended. Concurrent administration of probenecid prolongs the excretion of cefuroxime and produces an elevated peak serum level.</p><p><u>Potential nephrotoxic drugs and loop diuretics</u></p><p>High-dosage treatments with cephalosporin should be carried out with caution on patients who are taking strong-acting diuretics (such as furosemide) or potential nephrotoxic preparations (such as aminoglycoside antibiotics), since impairment of renal function through such combinations cannot be ruled out.</p><p><u>Other Interactions</u></p><p>Determination of blood/plasma glucose levels: Please refer to section 4.4.</p><p>Concomitant use with oral anticoagulants may give rise to increased international normalized ratio (INR).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited amounts of data from the use of cefuroxime in pregnant women. Studies in animals have shown no reproductive toxicity (see section 5.3). Cefuroxime should be prescribed to pregnant women only if the benefit outweighs the risk.</p><p>Cefuroxime has been shown to cross the placenta and attain therapeutic levels in amniotic fluid and cord blood after intramuscular or intravenous dose to the mother.</p><p><u>Breastfeeding</u></p><p>Cefuroxime is excreted in human milk in small quantities. Adverse reactions at therapeutic doses are not expected, although a risk of diarrhoea and fungus infection of the mucous membranes cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from cefuroxime therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>There are no data on the effects of cefuroxime sodium on fertility in humans. Reproductive studies in animals have shown no effects on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of cefuroxime on the ability to drive and use machines have been performed. However, based on known adverse reactions, cefuroxime is unlikely to have an effect on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions are neutropenia, eosinophilia, transient rise in liver enzymes or bilirubin, particularly in patients with pre-existing liver disease, but there is no evidence of harm to the liver and injection site reactions.</p><p>The frequency categories assigned to the adverse reactions below are estimates, as for most reactions suitable data for calculating incidence are not available. In addition, the incidence of adverse reactions associated with cefuroxime sodium may vary according to the indication.</p><p>Data from clinical trials were used to determine the frequency of very common to rare adverse reactions. The frequencies assigned to all other adverse reactions (i.e. those occurring at &lt;1/10,000) were mainly determined using post-marketing data, and refer to a reporting rate rather than a true frequency.</p><p>Treatment related adverse reactions, all grades, are listed below by MedDRA body system organ class, frequency and grade of severity. The following convention has been utilised for the classification of frequency: very common &ge; 1/10; common &ge; 1/100 to &lt; 1/10, uncommon &ge; 1/1,000 to &lt; 1/100; rare &ge; 1/10,000 to &lt; 1/1,000; very rare &lt; 1/10,000 and not known (cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0" style="width:665px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Infections and infestations</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><em>Candida </em>overgrowth, overgrowth of <em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Blood and lymphatic system disorders</u></p></td><td style="vertical-align:top"><p>neutropenia, eosinophilia, decreased haemoglobin concentration</p></td><td style="vertical-align:top"><p>leukopenia, positive Coombs test</p></td><td style="vertical-align:top"><p>thrombocytopenia, haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p><u>Immune system disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug fever, interstitial nephritis, anaphylaxis, cutaneous vasculitis</p></td></tr><tr><td style="vertical-align:top"><p><u>Gastrointestinal disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>gastrointestinal disturbance</p></td><td style="vertical-align:top"><p>pseudomembranous colitis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>Hepatobiliary disorders</u></p></td><td style="vertical-align:top"><p>transient rise in liver enzymes</p></td><td style="vertical-align:top"><p>transient rise in bilirubin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Skin and subcutaneous tissue disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>skin rash, urticaria and pruritus</p></td><td style="vertical-align:top"><p>erythema multiforme, toxic epidermal necrolysis and Stevens-Johnson syndrome, angioneurotic oedema</p></td></tr><tr><td style="vertical-align:top"><p><u>Renal and urinary disorders</u></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>elevations in serum creatinine, elevations in blood urea nitrogen and decreased creatinine clearance (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><u>General disorders and administration site conditions</u></p></td><td style="vertical-align:top"><p>injection site reactions which may include pain and thrombophlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Description of selected adverse reactions</em></p><p>Cephalosporins as a class tend to be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug to produce a positive Coombs test (which can interfere with cross matching of blood) and very rarely haemolytic anaemia.</p><p>Transient rises in serum liver enzymes or bilirubin have been observed which are usually reversible.</p><p>Pain at the intramuscular injection site is more likely at higher doses. However it is unlikely to be a cause for discontinuation of treatment.</p></td></tr></tbody></table><p><em>Pediatric population</em></p><p>The safety profile for cefuroxime sodium in children is consistent with the profile in adults.</p><p><strong>To report any side effect(s):</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:669px"><tbody><tr><td style="vertical-align:top"><p>Saudi Arabia:</p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>- Toll free phone: 8002490000</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can occur if the dose is not reduced appropriately in patients with renal impairment Serum levels of cefuroxime can be reduced by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, Second-generation cephalosporins,</p><p>ATC code: J01DC02</p><p><u>Mechanism of action</u></p><p>Cefuroxime inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p><u>Mechanism of resistance</u></p><p>Bacterial resistance to cefuroxime may be due to one or more of the following mechanisms:</p><p>&bull; hydrolysis by beta-lactamases including (but not limited to) extended-spectrum beta-lactamases (ESBLs), and Amp-C enzymes, that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species;</p><p>&bull; reduced affinity of penicillin-binding proteins for cefuroxime;</p><p>&bull; outer membrane impermeability, which restricts access of cefuroxime to penicillin binding proteins in Gram-negative bacteria;</p><p>&bull; bacterial efflux pumps.</p><p>Organisms that have acquired resistance to other injectable cephalosporins are expected to be resistant to cefuroxime. Depending on the mechanism of resistance, organisms with acquired resistance to penicillins may demonstrate reduced susceptibility or resistance to cefuroxime.</p><p><u>Cefuroxime sodium breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:641px"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Breakpoints (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>Susceptible</u></p></td><td style="vertical-align:top"><p><u>Resistant</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae (Enterobacterales)</em>1, 2</p></td><td style="vertical-align:top"><p>&le;8</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em> spp.</p></td><td style="vertical-align:top"><p>Note3</p></td><td style="vertical-align:top"><p>Note3</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>A, B, C and G</p></td><td style="vertical-align:top"><p>Note4</p></td><td style="vertical-align:top"><p>Note4</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;1</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>(other)</p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&le;1</p></td><td style="vertical-align:top"><p>&gt;2</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&le;4</p></td><td style="vertical-align:top"><p>&gt;8</p></td></tr><tr><td style="vertical-align:top"><p><em>Kingella kingae</em></p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints1</p></td><td style="vertical-align:top"><p>&le;45</p></td><td style="vertical-align:top"><p>&gt;85</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>1 </strong>The cephalosporin breakpoints for <em>Enterobacteriaceae</em> will detect all clinically important resistance mechanisms (including ESBL and plasmid mediated AmpC). Some isolates that produce beta-lactamases are susceptible or intermediate to 3rd or 4th generation cephalosporins with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorization of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.</p><p>2&nbsp;Breakpoint relates to a dosage of 1.5 g &times; 3 and to <em>E. coli, P. mirabilis</em> and <em>Klebsiella spp</em>. only</p><p>3&nbsp;Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidme, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections.</p><p>4&nbsp;The susceptibility of streptococcus groups A, B, C and G is inferred from the benzylpenicillin susceptibility.</p><p>5&nbsp;Breakpoints apply to daily intravenous dose of 750 mg &times; 3 and a high dose of at least 1.5 g &times; 3.</p></td></tr></tbody></table><p><u>Microbiological susceptibility</u></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is known and the utility of the agent in at least some types of infections is questionable.</p><p>Cefuroxime is usually active against the following microorganisms <em>in vitro</em>.</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Staphylococcus aureus (methicillin-susceptible) </em>$</p><p><em>Streptococcus pyogenes</em></p><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganisms for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus mitis </em>(viridans group)</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Citrobacter spp. not including C. freundii</em></p><p><em>Enterobacter </em>spp. not including <em>E. aerogenes </em>and <em>E. cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus </em>spp. not including <em>P. penneri and P. vulgaris</em></p><p><em>Providencia</em> spp.</p><p><em>Salmonella </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Peptostreptococcus </em>spp.</p><p><em>Propionibacterium </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Fusobacterium </em>spp.</p><p><em>Bacteroides </em>spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter </em>spp.</p><p><em>Burkholderia cepacia</em></p><p><em>Campylobacter </em>spp.</p><p><em>Citrobacter freundii</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Morganella morganii</em></p><p><em>Proteus penneri</em></p><p><em>Proteus vulgaris</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia marcescens</em></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes:</u></p><p><em>Clostridium difficile</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia </em>spp.</p><p><em>Mycoplasma</em> spp.</p><p><em>Legionella</em> spp.</p></td></tr></tbody></table><ul><li>All methicillin-resistant <em>S. aureus</em> are resistant to cefuroxime.</li></ul><p><em>In vitro</em> the activities of cefuroxime sodium and aminoglycoside antibiotics in combination have been shown to be at least additive with occasional evidence of synergy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>After intramuscular (IM) injection of cefuroxime to normal volunteers, the mean peak serum concentrations ranged from 27 to 35 &micro;g/mL for a 750 mg dose and from 33 to 40 &micro;g/mL for a 1000 mg dose, and were achieved within 30 to 60 minutes after administration. Following intravenous (IV) doses of 750 and 1500 mg, serum concentrations were approximately 50 and 100 &micro;g/mL, respectively, at 15 minutes.</p><p>AUC and Cmax&nbsp;appear to increase linearly with increase in dose over the single dose range of 250 to 1000 mg following IM and IV administration. There was no evidence of accumulation of cefuroxime in the serum from normal volunteers following repeat intravenous administration of 1500 mg doses every 8 hours.</p><p><u>Distribution</u></p><p>Protein binding has been stated as 33 to 50%, depending on the methodology used. The average volume of distribution ranges from 9.3 to 15.8 L/1.73 m2&nbsp;following IM or IV administration over the dosage range of 250 to 1000 mg. Concentrations of cefuroxime in excess of the minimum inhibitory levels for common pathogens can be achieved in the tonsilla, sinus tissues, bronchial mucosa, bone, pleural fluid, joint fluid, synovial fluid, interstitial fluid, bile, sputum and aqueous humour. Cefuroxime passes the blood-brain barrier when the meninges are inflamed.</p><p><u>Biotransformation</u></p><p>Cefuroxime is not metabolised.</p><p><u>Elimination</u></p><p>Cefuroxime is excreted by glomerular filtration and tubular secretion. The serum half-life after either intramuscular or intravenous administration is approximately 70 minutes. There is an almost complete recovery (85 to 90%) of unchanged cefuroxime in urine within 24 hours of administration. The majority of the cefuroxime is excreted within the first 6 hours. The average renal clearance ranges from 114 to 170 mL/min/1.73 m2&nbsp;following IM or IV administration over the dosage range of 250 to 1000 mg.</p><p><strong><em>Special patient populations</em></strong></p><p><u>Gender</u></p><p>No differences in the pharmacokinetics of cefuroxime were observed between males and females following a single IV bolus injection of 1000 mg of cefuroxime as the sodium salt.</p><p><u>Elderly</u></p><p>Following IM or IV administration, the absorption, distribution and excretion of cefuroxime in elderly patients are similar to younger patients with equivalent renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in cefuroxime dose selection, and it may be useful to monitor renal function (see section 4.2).</p><p><u>Paediatrics</u></p><p>The serum half-life of cefuroxime has been shown to be substantially prolonged in neonates according to gestational age. However, in older infants (aged &gt;3 weeks) and in children, the serum half-life of 60 to 90 minutes is similar to that observed in adults.</p><p><u>Renal impairment</u></p><p>Cefuroxime is primarily excreted by the kidneys. As with all such antibiotics, in patients with markedly impaired renal function (i.e. C1cr &lt;20 mL/minute) it is recommended that the dosage of cefuroxime should be reduced to compensate for its slower excretion (see section 4.2). Cefuroxime is effectively removed by haemodialysis and peritoneal dialysis.</p><p><u>Hepatic impairment</u></p><p>Since cefuroxime is primarily eliminated by the kidney, hepatic dysfunction is not expected to have an effect on the pharmacokinetics of cefuroxime.</p><p><u>PK/PD relationship</u></p><p>For cephalosporins, the most important pharmacokinetic-pharmacodynamic index correlating with <em>in vivo</em> efficacy has been shown to be the percentage of the dosing interval (%T) that the unbound concentration remains above the minimum inhibitory concentration (MIC) of cefuroxime for individual target species (i.e. %T&gt;MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and toxicity to reproduction and development. No carcinogenicity studies have been performed; however, there is no evidence to suggest carcinogenic potential.</p><p>Gamma glutamyl trans peptidase activity in rat urine is inhibited by various cephalosporins, however the level of inhibition is less with cefuroxime. This may have significance in the interference in clinical laboratory tests in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefuroxime is compatible with most commonly used intravenous fluids and electrolyte solutions.</p><p>The pH of 2.74% w/v sodium bicarbonate injection BP considerably affects the colour of solutions and therefore this solution is not recommended for the dilution of Cefuroxime. However, if required, for patients receiving sodium bicarbonate injection by infusion the Cefuroxime solution may be introduced into the tube of the giving set.</p><p>Cefuroxime should not be mixed in the syringe with aminoglycoside antibiotics.</p><p>In the absence of other compatibility studies, this medicinal product must not be mixed with other medicinal products apart from those listed as compatible in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials or bottles: 24 months (2 years)
When reconstituted for injection, it can be stored for 5 hours if stored below 25 °C, or 72 hours if stored 2 to 8 °C.
When reconstituted for infusion, it can be stored for 3 hours if stored below 25 °C, or 72 hours if stored 2 to 8 °C.
From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C unless reconstitution has taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C. Protect from light.</p><p>After reconstitution the product may be stored at 2&deg;C-8&deg;C (in a refrigerator) for up to 24 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 mL (type I) moulded clear glass vial containing 750 mg of Cefuroxime sodium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Instructions for use:</strong> The procedures below are provided as general guidelines for the reconstitution and administration of Cefuroxime for Injection. Agitate the vial gently until the powder dissolves completely. Withdraw all of the dissolved solution from the powder vial into the syringe and then inject either to patient as IM or in an infusion bag. Mix the solution, DO NOT USE if it has particles in it. Administer the solution via intravenous or IM route. Cleanse the injection site with a new alcohol swab prior to administration.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype id="_x0000_t75" coordsize="21600,21600"
  o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
  stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image1" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;left:0;text-align:left;margin-left:429.55pt;
  margin-top:43.95pt;width:480.75pt;height:44.55pt;z-index:251658240;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:9pt;
  mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
  mso-wrap-distance-bottom:0;mso-position-horizontal:right;
  mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/15703/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="margin"/>
 </v:shape><![endif]--></p><p><img alt="" width="2003" height="186" src="data:image/jpeg;base64,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" /></p><p>&nbsp;</p><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Reconstitution procedure:</strong> Reconstitute Cefuroxime for Injection powder for injection/infusion with solvent provided with pack.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Any unused product or waste material should be disposed of in accordance with local requirements.</p><p><strong><u>Instructions for constitution</u></strong></p><p>Table 4. Additional volumes and solution/suspension concentrations which may be useful when fractional doses are required.</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td style="vertical-align:top"><p><strong>Vial</strong></p><p><strong>size</strong></p></td><td style="vertical-align:top"><p><strong>Routes of</strong></p><p><strong>administration</strong></p></td><td style="vertical-align:top"><p><strong>Amount of water to</strong></p><p><strong>be added (mL)</strong></p></td><td style="vertical-align:top"><p><strong>Approximate cefuroxime</strong></p><p><strong>concentration (mg/mL)**</strong></p></td><td style="vertical-align:top"><p><strong>Resulting product</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>750mg</p></td><td style="vertical-align:top"><p>intramuscular</p></td><td style="vertical-align:top"><p>3mL</p></td><td style="vertical-align:top"><p>216</p></td><td style="vertical-align:top"><p>Suspension</p></td></tr><tr><td style="vertical-align:top"><p>intravenous</p><p>bolus</p></td><td style="vertical-align:top"><p>at least 6mL</p></td><td style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>Solution</p></td></tr><tr><td style="vertical-align:top"><p>intravenous</p><p>infusion</p></td><td style="vertical-align:top"><p>at least 6mL</p></td><td style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>Solution</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>1.5g</p></td><td style="vertical-align:top"><p>intramuscular</p></td><td style="vertical-align:top"><p>6mL</p></td><td style="vertical-align:top"><p>216</p></td><td style="vertical-align:top"><p>Suspension</p></td></tr><tr><td style="vertical-align:top"><p>intravenous</p><p>bolus</p></td><td style="vertical-align:top"><p>At least 15mL</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>Solution</p></td></tr><tr><td style="vertical-align:top"><p>intravenous</p><p>infusion</p></td><td style="vertical-align:top"><p>15mL*</p></td><td style="vertical-align:top"><p>94</p></td><td style="vertical-align:top"><p>Solution</p></td></tr></tbody></table><p>&nbsp;</p><p><em>* Reconstituted solution to be added to 50 or 100ml of compatible infusion fluid (see information on compatibility, below)</em></p><p><em>** The resulting volume of the solution/suspension of cefuroxime in reconstitution medium is increased due to the displacement factor of the drug substance resulting in the listed concentrations in mg/ml.</em></p><p><em><u>Compatibility</u></em></p><p>1.5 g cefuroxime sodium constituted with 15 mL Water for Injection may be added to metronidazole injection (500 mg/100 mL).</p><p>1.5 g cefuroxime sodium is compatible with azlocillin 1 g (in 15 mL) or 5 g (in 50 mL).</p><p>Cefuroxime sodium (5 mg/mL) in 5% w/v or 10% w/v xylitol injection may used.</p><p>Cefuroxime sodium is compatible with aqueous solutions containing up to 1% lidocaine hydrochloride.</p><p>Cefuroxime sodium is compatible with the following infusion fluids:</p><p>0.9% w/v Sodium Chloride Injection BP</p><p>5% Dextrose Injection BP</p><p>0.18% w/v Sodium Chloride plus 4% Dextrose Injection BP</p><p>5% Dextrose and 0.9% w/v Sodium Chloride Injection BP</p><p>5% Dextrose and 0.45% Sodium Chloride Injection</p><p>5% Dextrose and 0.225% Sodium Chloride Injection</p><p>10% Dextrose Injection</p><p>Lactated Ringer&#39;s Injection USP</p><p>M/6 Sodium Lactate Injection</p><p>Compound Sodium Lactate Injection BP (Hartmann&#39;s Solution).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hill Top Industrial Estate, Jharmajri, EPIP, Phase-I 					
(Extn.), Bhatoli Kalan, Baddi, Distt. Solan, 						
Himachal Pradesh-173205, India
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                XX
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>